Edition:
United States

Momenta Pharmaceuticals Inc (MNTA.O)

MNTA.O on Nasdaq

14.90USD
9 Dec 2016
Change (% chg)

$0.40 (+2.76%)
Prev Close
$14.50
Open
$14.65
Day's High
$15.00
Day's Low
$14.60
Volume
403,336
Avg. Vol
617,763
52-wk High
$16.95
52-wk Low
$7.86

Select another date:

Tue, Nov 29 2016

Momenta's Humira biosimilar succeeds in key psoriasis study

U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

UPDATE 1-Momenta's Humira biosimilar succeeds in key psoriasis study

Nov 29 U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

BRIEF-Momenta Pharmaceuticals says positive top-line phase 3 results for M923, a proposed Humira biosimilar

* Momenta Pharmaceuticals announces positive top-line phase 3 results for M923, a proposed Humira (adalimumab) biosimilar

Momenta's Humira biosimilar succeeds in key psoriasis study

Nov 29 U.S. biotech company Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

BRIEF-Momenta Pharmaceuticals names Scott Storer as CFO

* Says Storer is expected to begin at Momenta on november 28, 2016 and will replace Momenta's current CFO Rick Shea

BRIEF-Momenta and Mylan initiate early-stage study for proposed biosimilar of Orencia

* Mylan nv - momenta has achieved milestone necessary to earn a $25 million payment from mylan.

BRIEF-Mmenta Pharmaceuticals to regain global development and commercialization rights to M923

* Momenta Pharmaceuticals to regain global development and commercialization rights to M923, a proposed biosimilar of HUMIRA (adalimumab), through termination of collaboration agreement with Baxalta, now part of Shire

BRIEF-Momenta Pharmaceuticals reports Q2 loss per share $0.31

* Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S

BRIEF-Momenta Pharmaceuticals appoints Steven Gilman to board of directors

* Momenta pharmaceuticals appoints steven c. Gilman, ph.d. To board of directors Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Momenta, Sandoz allowed to broaden claims over quality test patent

A federal judge has allowed Momenta Pharmaceuticals and Sandoz Inc to broaden a lawsuit accusing Amphastar Pharmaceuticals of infringing a patent on quality control methods used in making the blood thinner enoxaparin, the generic form of French drug maker Sanofi's Lovenox.

Select another date: